Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting Veracyte’s SEC disclosures can feel like decoding a genomic sequence: reimbursements, CLIA lab costs, and RNA-sequencing R&D are buried in dense language. If you have ever searched for “Veracyte SEC filings explained simply” or wondered whether a spike in thyroid test volumes appears in the latest numbers, this page is built for you.
Stock Titan pairs every submission to EDGAR with AI-powered summaries that translate jargon into plain English. Whether you need the Veracyte quarterly earnings report 10-Q filing to confirm margin trends or want Veracyte Form 4 insider transactions real-time to gauge executive confidence, our platform delivers insights as soon as the document hits the wire.
- 10-K: Get the Veracyte annual report 10-K simplified—see how test-volume growth offsets R&D spend without reading 200 pages.
- 10-Q: Instantly surface segment revenue in our Veracyte earnings report filing analysis.
- 8-K: Follow laboratory accreditation news with Veracyte 8-K material events explained.
- Form 4: Track Veracyte executive stock transactions Form 4 and complete Veracyte insider trading Form 4 transactions in one click.
- DEF 14A: Review Veracyte proxy statement executive compensation without sifting through legal prose.
Our expert analysis connects each filing to what drives value for a genomic diagnostics company—test adoption, payer coverage and intellectual property. Use the dashboard to set alerts, compare quarters, and export data; you’ll be understanding Veracyte SEC documents with AI instead of scanning line-by-line.
Veracyte insider Phillip G. Febbo reported a non-sale disposition of 2,955 shares of common stock on 09/02/2025. The transaction reflects shares withheld to satisfy tax withholding obligations related to the vesting of restricted stock units, executed at a reported price of $30.11 per share. After the withholding, the reporting person beneficially owns 100,790 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and identifies Febbo as the company’s Chief Scientific & Medical Officer and an officer of Veracyte (VCYT).
John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc. (VCYT), reported a transaction dated 09/02/2025 in which 2,902 shares of the company's common stock were withheld at a price of $30.11 to satisfy tax withholding obligations related to the vesting of restricted stock units. The filing clarifies that the withheld shares do not represent a sale. After the withholding, the reporting person beneficially owned 91,638 shares, held directly. The Form 4 was signed by an attorney-in-fact, Jonathan Wygant, on 09/04/2025. The form indicates the filing was made by one reporting person and identifies the reporting persons address as South San Francisco, CA.
Jonathan Wygant, Veracyte (VCYT) reporting person, disclosed a non-sale disposition on 09/02/2025 in which 1,648 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units; the transaction is reported at a per-share value of $30.11. The filing clarifies this withholding does not represent a sale.
After the withholding, the reporting person beneficially owns 46,779 shares, which includes 512 shares purchased on July 30, 2025 under the company ESPP. The reporting person is identified as an officer with the title VP, Chief Accounting Officer.
Veracyte, Inc. (VCYT) notice reports a proposed sale of 7,667 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $234,763.54 and an approximate sale date of 09/04/2025. The filing shows the shares were acquired as Restricted Stock Units from the issuer on 09/02/2025 and payment/vesting is recorded as 09/02/2025. The issuer's total shares outstanding is listed as 78,671,588. The filer reports no securities sold by the same person in the past three months. The notice includes the required representation that the seller does not possess any undisclosed material adverse information regarding the issuer.
This Schedule 13G/A shows Artisan Partners entities beneficially own 6,321,775 shares of Veracyte common stock, equal to 8.1% of the class based on 78,314,611 shares outstanding. The reported position reflects shared voting power of 5,220,102 and shared dispositive power over the full 6,321,775 shares, with no sole voting or dispositive power asserted. The filing states the shares are held for discretionary clients of the adviser and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. The document names the reporting entities within the Artisan Partners group.
Veracyte Director Karin Eastham received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025, as reported in this Form 4 filing. The RSUs were awarded at $0 cost and will vest in full on either:
- The first anniversary of the grant date (June 18, 2026), or
- Immediately prior to Veracyte's next annual stockholder meeting, whichever comes first
- Additionally, full vesting occurs upon any change in control of the company
Following this transaction, Eastham now beneficially owns 23,228 shares of Veracyte common stock directly. This equity grant appears to be part of the company's director compensation program. The filing was signed by Jonathan Wygant as attorney-in-fact on June 23, 2025.
FAQ
What is the current stock price of Veracyte (VCYT)?
What is the market cap of Veracyte (VCYT)?
